TH07 - A New Novel Topical Treatment for Androgenic Alopecia

• Published in: International journal of trichology 2023-11, Vol.15 (6), p.241-247
• Main Authors: Sekhavat, Houfar, Ford, Peter, Lepage, Anik, Nateghi, Ariana, Yehuda, Sara Bar, Bourgeois, Marianne
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 0974-7753; 0974-9241
• DOI: 10.4103/ijt.ijt_145_22

Androgenic alopecia (AGA) is common among men. Currently, topical minoxidil and oral finasteride are approved by the FDA for the treatment of AGA. Unfortunately, neither of them is completely effective and systemic adverse events have been reported after finasteride administration. Triple Hair Inc. has developed a new topical treatment regimen using a combination of finasteride, latanoprost and minoxidil - TH07. Each of the compounds was effective and safe as a topical treatment in animal models and clinical studies of AGA. The aim of this proof-of-concept study was to evaluate the effectiveness of the TH07 in comparison to the 3 drugs as monotherapy on hair growth in men with AGA. Patients with light to moderate AGA were randomized to be treated topically, once daily, for 6 months with TH07, 0.1% finasteride, 0.03% latanoprost, or 5% minoxidil. Data of investigators' assessment based on pictures, as well as patients' self-assessment and satisfaction, were collected. A moderate hair re-growth in the majority of the participant treated with TH07 in comparison to the retreatment with its active components administered as monotherapy was reported by the investigators. Most of the patients treated with TH07 were satisfied with their hair appearance in comparison to the other treatments. No systemic adverse events were reported and the TH07 was well tolerated. The data of the current study demonstrated that the topical administration of TH07 resulted in an improved efficacy in the treatment of the AGA compared to treatment with each of the ingredients administered separately.